Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Supra-therapeutic Anticoagulation with Warfarin: A Cross-sectional Study

Author(s): Kannan Sridharan*, Rashed Al Banna and Aysha Husain

Volume 18, Issue 1, 2023

Published on: 21 June, 2022

Page: [23 - 30] Pages: 8

DOI: 10.2174/1574886317666220429103847

Price: $65

Abstract

Aims: To identify the extent and associated factors for patients with prolonged prothrombin time, international normalized ratio (PT-INR), and the dosage modifications were carried out with warfarin.

Background: Studies evaluating patients on warfarin with supratherapeutic anticoagulation are limited. It is vital to understand the management strategies for patients receiving warfarin who are bleeding and those with only supratherapeutic PT-INR.

Objective: To evaluate the factors associated with supratherapeutic anticoagulation without bleeding with warfarin.

Methods: A cross-sectional study was carried out on patients receiving long-term warfarin with at least one PT-INR value > 3.2. Percent time in therapeutic range (TTR) was calculated and National Institute for Health and Care Excellence (NICE) guidelines were adhered to defining anticoagulation control into good (> 65%) and poor (< 65%).

Results: One hundred and forty-four patients were recruited. Nearly half of the study population had PT-INR values between 3.2 and 3.9. On average, individuals had at least 4 times PT-INR values in the supratherapeutic range. Elderly patients were observed with a significant trend of supratherapeutic INR. Duration of therapy was significantly correlated with the risk of PT-INR > 4. Lower TTR was observed in patients with frequent PT-INR > 4 and those patients had significantly poor anticoagulation control. Duration of warfarin therapy and HAS-BLED scores were observed to be significant predictors of supratherapeutic INR. Large variations were observed in the modifications of warfarin dose carried out at various supratherapeutic INR values and consequently PTINR values.

Conclusion: We observed that the majority of patients with supratherapeutic INR had their INR values between 3.2 and 3.9. Elderly patients, with higher HAS-BLED scores and prolonged duration of warfarin therapy, were observed with an increased risk of supratherapeutic anticoagulation. Careful dosage modifications are needed particularly in high-risk categories as mentioned above.

Keywords: Warfarin, anticoagulant, supratherapeutic INR, bleeding, HAS-BLED, INR.

« Previous Next »
Graphical Abstract

[1]
Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: A review. West J Emerg Med 2015; 16(1): 11-7.
[http://dx.doi.org/10.5811/westjem.2014.12.22933] [PMID: 25671002]
[2]
Molteni M, Cimminiello C. Warfarin and atrial fibrillation: From ideal to real the warfarin affaire. Thromb J 2014; 12(1): 5.
[http://dx.doi.org/10.1186/1477-9560-12-5] [PMID: 24548437]
[3]
Lip GYH, Skjøth F, Nielsen PB, Kjældgaard JN, Larsen TB. The HAS-BLED, ATRIA, and ORBIT bleeding scores in atrial fibrillation patients using Non-Vitamin K antagonist oral anti-coagulants. Am J Med 2018; 131(5): 574.e13-27.
[http://dx.doi.org/10.1016/j.amjmed.2017.11.046] [PMID: 29274754]
[4]
Lindh JD, Holm L, Dahl ML, Alfredsson L, Rane A. Inci-dence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis 2008; 25(2): 151-9.
[http://dx.doi.org/10.1007/s11239-007-0048-2] [PMID: 17514429]
[5]
Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA, and ORBIT bleeding risk scores in pa-tients with atrial fibrillation taking warfarin. Am J Med 2016; 129(6): 600-7.
[http://dx.doi.org/10.1016/j.amjmed.2015.10.001] [PMID: 26482233]
[6]
van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: A sys-tematic review and metaregression. Chest 2006; 129(5): 1155-66.
[http://dx.doi.org/10.1378/chest.129.5.1155] [PMID: 16685005]
[7]
van Walraven C, Oake N, Wells PS, Forster AJ. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly. Chest 2007; 131(5): 1508-15.
[http://dx.doi.org/10.1378/chest.06-2628] [PMID: 17317732]
[8]
Pagano MB, Chandler WL. Bleeding risks and response to therapy in patients with INR higher than 9. Am J Clin Pathol 2012; 138(4): 546-50.
[http://dx.doi.org/10.1309/AJCPJ2GMDS7BXLEO] [PMID: 23010709]
[9]
Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complemen-tary and alternative medicine: A longitudinal analysis. Pharmacotherapy 2007; 27(9): 1237-47.
[http://dx.doi.org/10.1592/phco.27.9.1237] [PMID: 17723077]
[10]
Sridharan K, Banny RA, Husain A. Evaluation of stable doses of warfarin in a patient cohort. Drug Res 2020; 70(12): 570-5.
[http://dx.doi.org/10.1055/a-1228-5033] [PMID: 32820470]
[11]
Sridharan K, Al Banna R, Qader AM, Husain A. Does fasting during Ramadan influence the therapeutic effect of warfarin? J Clin Pharm Ther 2021; 46(1): 86-92.
[http://dx.doi.org/10.1111/jcpt.13254] [PMID: 32926452]
[12]
Sridharan K, Al Banna R, Malalla Z, et al. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: A cross-sectional study. Pharmacol Rep 2021; 73(5): 1405-17.
[http://dx.doi.org/10.1007/s43440-021-00256-w] [PMID: 33811620]
[13]
Tai C, Wu H, San C, Chua D. Management of supratherapeu-tic international normalized ratio without bleeding after warfa-rin use: An evaluation of vitamin K administration (SUPRA-WAR-K study). Can J Hosp Pharm 2017; 70(3): 207-14.
[http://dx.doi.org/10.4212/cjhp.v70i3.1660] [PMID: 28680174]
[14]
Tsu LV, Dienes JE, Dager WE. Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting. Ann Pharmacother 2012; 46(12): 1617-26.
[http://dx.doi.org/10.1345/aph.1R497] [PMID: 23249867]
[15]
Khatib R, Ludwikowska M, Witt DM, et al. Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: A systematic review and meta-analysis. Blood Adv 2019; 3(5): 789-96.
[http://dx.doi.org/10.1182/bloodadvances.2018025163] [PMID: 30850385]
[16]
Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed. American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 Suppl): e152S-84S.
[17]
Atreja A, El-Sameed YA, Jneid H, Hoogwerf BJ, Peacock WF. Elevated international normalized ratio in the ED: Clinical course and physician adherence to the published recommen-dations. Am J Emerg Med 2005; 23(1): 40-4.
[http://dx.doi.org/10.1016/j.ajem.2004.01.005] [PMID: 15672336]
[18]
Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: Management of the asymptomatic and bleeding pa-tient. J Thromb Thrombolysis 2010; 29(2): 171-81.
[http://dx.doi.org/10.1007/s11239-009-0412-5] [PMID: 19882303]
[19]
Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005; 115(6): 455-9.
[http://dx.doi.org/10.1016/j.thromres.2004.09.002] [PMID: 15792675]
[20]
Guest JF, Watson HG, Limaye S. Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. Clin Ther 2010; 32(14): 2478-93.
[http://dx.doi.org/10.1016/j.clinthera.2011.01.011] [PMID: 21353116 ]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy